Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15863054 | 0.96 | SLC6A4 (0.37) | CYP1A2SLC6A4CCR2OPRM1WDR5 | |
| SCHEMBL624106 | 0.90 | CYP1A2 (0.33) | CYP1A2SLC6A4OPRM1WDR5SLC6A3 | |
| SCHEMBL15866975 | 0.85 | HDAC3 (0.38) | CYP1A2SLC6A4OPRM1SLC6A3SLC6A2 | |
| SCHEMBL2375477 | 0.84 | TSHR (0.43) | SLC6A4TACR1 | |
| SCHEMBL625836 | 0.83 | SLC6A4 (0.50) | SLC6A4CCR2OPRM1SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL2375248 | 0.83 | TSHR (0.42) | SLC6A4TACR1 | |
| SCHEMBL626219 | 0.81 | SLC6A3 (0.45) | CYP1A2SLC6A4OPRM1SLC6A3SLC6A2 | |
| SCHEMBL24454607 | 0.81 | HDAC3 (0.39) | CYP1A2SLC6A4CCR2OPRM1SLC6A3 | |
| SCHEMBL15862525 | 0.80 | SLC6A4 (0.54) | SLC6A4CCR2OPRM1SLC6A3SLC6A2 | |
| SCHEMBL3518646 | 0.78 | SLC6A4 (0.56) | SLC6A4CCR2OPRM1SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | CYP1A2 3026/4885SLC6A4 511/4885CCR2 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.